Aragon & Janssen v. Cadila Healthcare: Erleada® Patent Dispute Dismissed
Aragon Pharmaceuticals and Janssen Biotech brought an infringement action against Cadila Healthcare and its Zydus affiliates in New Jersey over US11963952B2, the patent covering apalutamide-based Erleada®. The plaintiffs voluntarily dismissed the case without prejudice after just 76 days, leaving the door open for future proceedings.
A 76-day pharma patent dispute closed before it truly began
Filed on 12 September 2024 in the District of New Jersey, this Hatch-Waxman infringement action was brought by Aragon Pharmaceuticals and co-plaintiff Janssen Biotech against Cadila Healthcare, Zydus Lifesciences Limited, and Zydus Pharmaceuticals (USA). The suit targeted a generic version of Erleada® — the branded apalutamide tablet approved for non-metastatic castration-resistant prostate cancer — and asserted US11963952B2 as the primary patent at issue.
The case closed on 27 November 2024 when the plaintiffs filed a voluntary dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(i), ending the action without prejudice after 76 days. Because the dismissal was without prejudice, the plaintiffs retain the right to refile the same claims against the same defendants. No judicial ruling on infringement, validity, or enforceability was issued.
A resolution this early — before any substantive motion practice or claim construction — typically signals that the parties reached a private accommodation, that the ANDA filer agreed to a consent judgment or licensing arrangement, or that the plaintiffs elected a strategic pause. The public record is silent on whether any commercial terms were exchanged, and the absence of a with-prejudice dismissal leaves meaningful uncertainty about the long-term disposition of the generic entry dispute.
Filing to Voluntary dismissal in 76 days
76 days — resolved well before typical ANDA litigation reaches claim construction
Voluntarily dismissed: what the Rule 41 filing means for both parties
Rule 41(a)(1)(A)(i): plaintiff-initiated exit before answer or MSJ
A dismissal under FRCP 41(a)(1)(A)(i) is filed unilaterally by the plaintiff before the opposing party serves an answer or motion for summary judgment. It requires no court order and takes effect immediately upon filing. Critically, it does not constitute an adjudication on the merits — the action is simply withdrawn from the docket, and the court retains no further jurisdiction over the substantive claims.
No merits rulingWithout prejudice: the public record does not disclose the full story
A without-prejudice dismissal preserves the plaintiff’s right to reassert the same patent claims against the same defendants in a future action. A with-prejudice dismissal would permanently bar refiling. The public record here confirms only that the dismissal was without prejudice; it does not disclose whether a settlement, licensing term, or consent arrangement exists behind it. Observers should not assume either a clean resolution or a continuation of the dispute.
Refiling rights preservedZydus faces no injunction — but the patent remains enforceable
Cadila Healthcare and the Zydus entities secured no invalidity finding and received no declaratory judgment of non-infringement. The dismissal without prejudice means US11963952B2 remains fully enforceable and could be asserted again if the generic product launch proceeds. The statutory 30-month stay triggered under Hatch-Waxman may also affect the commercialisation timeline, depending on when the ANDA was submitted relative to the suit’s filing.
No invalidity findingErleada® market exclusivity: uncertainty persists for generic entrants
Because the case was dismissed without prejudice and without any court ruling, the competitive landscape for generic apalutamide remains unsettled. Other ANDA filers in the Erleada® pipeline should monitor whether Aragon and Janssen refile against Zydus or pursue parallel actions. The enforceability of US11963952B2 is unchanged, and its claims continue to represent a material barrier to generic market entry in the prostate cancer androgen receptor inhibitor space.
Exclusivity unchangedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ARAGON PHARMACEUTICALS, INC. | Company | Pharmaceutical patent holders — asserting US11963952B2 covering Erleada® (apalutamide)Search in Eureka ↗ |
| Co-Plaintiff | Janssen Biotech, Inc. | Company | Search in Eureka ↗ |
| Defendant | Cadila Healthcare, Ltd. | Company | Cadila Healthcare / Zydus entities — ANDA filer seeking to commercialise generic apalutamideSearch in Eureka ↗ |
| Co-Defendant | Zydus Lifesciences Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Zydus Pharmaceuticals (USA), Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Keith J. Miller | Attorney | Counsel for ARAGON PHARMACEUTICALS, INC.Search in Eureka ↗ |
| Plaintiff law firm | Robinson Miller LLC | Law Firm | Representing ARAGON PHARMACEUTICALS, INC.Search in Eureka ↗ |
| Defendant counsel | James S. Richter | Attorney | Counsel for Cadila Healthcare, Ltd.Search in Eureka ↗ |
| Defendant law firm | MIDLIGE RICHTER LLC | Law Firm | Representing Cadila Healthcare, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The plaintiffs invoked FRCP 41(a)(1)(A)(i) to dismiss their own infringement action before the defendants were required to answer. This procedural posture means the court issued no ruling on any substantive question — infringement, validity, or claim construction. The without-prejudice qualifier is legally significant: it preserves all of the plaintiffs’ claims for potential future assertion, and no res judicata or collateral estoppel attaches to any party. The phrasing of the dismissal is entirely standard and discloses nothing about commercial terms.
US11963952B2 — apalutamide androgen receptor inhibitor (Erleada®)
US11963952B2 protects apalutamide, the active pharmaceutical ingredient in Janssen’s Erleada® — an androgen receptor inhibitor approved for both non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. The patent was filed under application number US18/168204 and represents a later-generation asset in the Erleada® exclusivity stack. Apalutamide acts by blocking androgen receptor signalling, and its differentiated mechanism relative to earlier-generation antiandrogens underpins its clinical and commercial value.
For branded pharma, a granted patent on the active ingredient or formulation of a top-selling oncology drug like Erleada® functions as a core exclusivity asset against generic ANDA filers. With global prostate cancer drug sales in the multi-billion-dollar range, the commercial stakes attached to US11963952B2 are substantial. Competitors and ANDA applicants in the apalutamide space must assess whether their proposed generic formulations fall within the claim scope of this patent before proceeding to commercialisation.
Should you run an FTO against US11963952B2 before entering the apalutamide market?
Any company developing, filing an ANDA for, or planning to commercialise a generic version of apalutamide — or an androgen receptor inhibitor with structural or functional similarity — should conduct a freedom-to-operate analysis against US11963952B2. The patent was asserted aggressively enough to trigger litigation within weeks of the ANDA filing, and its claims remain unadjudicated. The dismissal without prejudice means Aragon and Janssen can and may refile; no safe harbour was created for Zydus or any other party.
PatSnap Eureka’s FTO Search Agent allows R&D and regulatory teams to map the full claim landscape of US11963952B2, identify design-around opportunities, and benchmark the patent against the broader apalutamide exclusivity stack. Eureka’s AI-powered analysis surfaces relevant prior art, claim dependencies, and litigation history — enabling in-house IP teams to make informed go/no-go decisions before committing capital to generic development programmes or launch strategies.
Run a freedom-to-operate analysis on US11963952B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA cases involving branded prostate cancer drug patents
Cases involving ANDA challenges to androgen receptor inhibitor patents in the District of New Jersey, with comparable voluntary dismissal or Hatch-Waxman procedural patterns.
What this case signals for the Erleada® and ANDA patent IP landscape
A swift voluntary dismissal in ANDA litigation rarely signals weakness — it more often reflects leverage, strategy, or an off-record deal.
Early ANDA dismissals without prejudice are a classic settlement signal
When branded pharma plaintiffs drop a Hatch-Waxman suit inside 90 days without prejudice, it consistently suggests either a confidential settlement, a licensing arrangement, or a strategic decision to refile on stronger footing. The absence of any fee or cost ruling reinforces the likelihood of a negotiated outcome rather than a unilateral withdrawal.
US11963952B2 remains live — other generic ANDA filers carry real risk
The dismissal confers no estoppel on Aragon or Janssen. Any other ANDA applicant for generic apalutamide faces the same unadjudicated patent. Companies holding or pursuing ANDAs for Erleada® should treat US11963952B2 as an active enforcement risk and ensure their FTO analysis reflects the patent’s current claim scope.
ARAGON v Cadila — key questions answered
The plaintiffs filed a Rule 41(a)(1)(A)(i) dismissal, ending the case before any substantive ruling. Without prejudice means Aragon and Janssen retain the right to refile the same patent claims against Cadila and Zydus in the future. No finding on infringement, validity, or enforceability of US11963952B2 was made.
The sole patent asserted was US11963952B2, filed under application number US18/168204. It covers apalutamide, the active ingredient in Janssen’s Erleada®, an androgen receptor inhibitor used to treat prostate cancer. The patent remains granted and enforceable following the dismissal.
No. The dismissal without prejudice does not constitute a win for either party on the merits. Cadila Healthcare and the Zydus entities received no invalidity finding and no declaratory judgment of non-infringement. The plaintiffs simply withdrew the action, preserving their right to refile.
The case lasted 76 days, from filing on 12 September 2024 to closure on 27 November 2024. This is a notably short duration for Hatch-Waxman ANDA litigation, which typically proceeds through claim construction and beyond before resolution.
The public record does not disclose how the dismissal interacts with any existing 30-month stay triggered by the ANDA filing. Whether the stay remains in effect, was never initiated, or was otherwise resolved through a confidential agreement is not determinable from the docket alone. Parties should consult the full ANDA filing chronology and any related FDA correspondence.
PatSnap Eureka searches patents and litigation data to answer instantly.